Evidence map›Paper›PMID 26937903›Full record

ArticleMedicine2016

An Ultra-Deep Targeted Sequencing Gene Panel Improves the Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma.

Chun-Ta Liao, Shu-Jen Chen, Li-Yu Lee, Chuen Hsueh, Lan-Yan Yang, Chien-Yu Lin, Kang-Hsing Fan, Hung-Ming Wang, Shu-Hang Ng, Chih-Hung Lin and 7 more

Abstract read
In one paragraph

Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chun-Ta LiaoFrom the Department of Otorhinolaryngology, Head and Neck Surgery (C-TL, I-HC, K-PC, S-FH, C-JK), Department of Biomedical Sciences, School of Medicine (S-JC, H-CC), Department of Genomic Core Laboratory, Molecular Medicine Research Center (S-JC, H-CC), Department of Pathology (L-YL, CH), Department of Biostatistics and Informatics Unit, Clinical Trial Center (L-YY), Department of Radiation Oncology (C-YL, K-HF), Department of Medical Oncology (H-MW), Department of Diagnostic Radiology (S-HN), Department of Plastic and Reconstructive Surgery (C-HL, C-KT), Department of Nuclear Medicine and Molecular Imaging Center (T-CY), Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Shu-Jen Chen
Li-Yu Lee
Chuen Hsueh
Lan-Yan Yang
Chien-Yu Lin
Kang-Hsing Fan
Hung-Ming Wang
Shu-Hang Ng
Chih-Hung Lin
Chung-Kan Tsao
I-How Chen
Kai-Ping Chang
Shiang-Fu Huang
Chung-Jan Kang
Hua-Chien Chen
Tzu-Chen Yen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An improved prognostic stratification of patients with oral cavity squamous cell carcinoma (OSCC) and pathologically positive (pN+) nodes is urgently needed. Here, we sought to examine whether an ultra-deep targeted sequencing (UDT-Seq) gene panel may improve the prognostic stratification in this patient group.A mutation-based signature affecting 10 genes (including genetic mutations in 6 oncogenes and 4 tumor suppressor genes) was devised to predict disease-free survival (DFS) in 345 primary tumor specimens obtained from pN+ OSCC patients. Of the 345 patients, 144 were extracapsular spread (ECS)-negative and 201 were ECS-positive. The 5-year locoregional control, distant metastases, disease-free, disease-specific, and overall survival (OS) rates served as outcome measures.The UDT-Seq panel was an independent risk factor (RF) for 5-year locoregional control (P = 0.0067), distant metastases (P = 0.0001), DFS (P < 0.0001), disease-specific survival (DSS, P < 0.0001), and OS (P = 0.0003) in pN+ OSCC patients. The presence of ECS and pT3-4 disease were also independent RFs for DFS, DSS, and OS. A prognostic scoring system was formulated by summing up the significant covariates (UDT-Seq, ECS, pT3-4) separately for each survival endpoint. The presence of a positive UDT-Seq panel (n = 77) significantly improved risk stratification for all the survival endpoints as compared with traditional AJCC staging (P < 0.0001). Among ECS-negative patients, those with a UDT-Seq-positive panel (n = 31) had significantly worse DFS (P = 0.0005) and DSS (P = 0.0002). Among ECS-positive patients, those with a UDT-Seq-positive panel (n = 46) also had significantly worse DFS (P = 0.0032) and DSS (P = 0.0098).Our UDT-Seq gene panel consisting of clinically actionable genes was significantly associated with patient outcomes and provided better prognostic stratification than traditional AJCC staging. It was also able to predict prognosis in OSCC patients regardless of ECS presence.

Indexed as

Genes, Tumor SuppressorAdultAgedAged, 80 and overCarcinoma, Squamous CellFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMouth NeoplasmsMutationNeoplasm StagingOncogenesPrognosis

Identifiers

PMID26937903
PMCPMC4779000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.